ArticleAntimicrobial agents and chemotherapy2012
Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Effects of Inappropriate Administration of Empirical Antibiotics on Mortality in Adults With Bacteraemia: Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Insights into novel diagnostic assay development, antimicrobial resistance, and pathogenicity inApplied and environmental microbiology · 2026Article
- Review
- Ethnomedicine, antibacterial activity, antioxidant potential and phytochemical screening of selected medicinal plants in Dibatie district, Metekel zone, western Ethiopia.BMC complementary medicine and therapies · 2024Article
- Characterization and risk assessment of novel SXT/R391 integrative and conjugative elements with multidrug resistance inMicrobiology spectrum · 2024Article
- Multidrug-ResistantInfection and drug resistance · 2024Article
- Antimicrobial Properties of Capsaicin: Available Data and Future Research Perspectives.Nutrients · 2023Review
- Proteus mirabilis: A rare cause of pneumonia, radiologically mimicking malignancy of the lung.Clinical case reports · 2023Article
- Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications.International journal of molecular sciences · 2022Review
- The Brief Case: Proteus mirabilis Causing Coraliform Lithiasis and Bacteremia in an Elderly Catheterized Patient.Journal of clinical microbiology · 2022Review
- Genomic characteristics of clinical multidrug-resistantFrontiers in microbiology · 2022Article
- Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection.Infection and immunity · 2021Article
- Septic discitis and septic pulmonary emboli: rare complications ofBMJ case reports · 2021Article
- Identification and molecular modeling of new quinolin-2-one thiosemicarbazide scaffold with antimicrobial urease inhibitory activity.Molecular diversity · 2021Article
- Protective multi-epitope candidate vaccine for urinary tract infection.Biotechnology reports (Amsterdam, Netherlands) · 2020Article
- A Clinical Perspective on the Antimicrobial Resistance Spectrum of Uropathogens in a Romanian Male Population.Microorganisms · 2020Article
- Article
- High Prevalence of Multidrug-Resistant and Extended-SpectrumJournal of tropical medicine · 2020Article
- A Rare Opportunist,Infection and immunity · 2019Article
- Twin arginine translocation, ammonia incorporation, and polyamine biosynthesis are crucial for Proteus mirabilis fitness during bloodstream infection.PLoS pathogens · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our aims were to identify (i) risk factors associated with the acquisition of multidrug-resistant (MDR, to 3 or more classes of antimicrobials) Proteus mirabilis isolates responsible for bloodstream infections (BSIs) and (ii) the impact on mortality of such infections. Risk factors for acquiring MDR P. mirabilis BSIs were investigated in a case-case-control study; those associated with mortality were assessed by comparing survivors and nonsurvivors in a cohort study. The population consisted of 99 adult inpatients with P. mirabilis BSIs identified by our laboratory over an 11-year period (1999 to 2009), 36 (33.3%) of which were caused by MDR strains, and the overall 21-day mortality rate was 30.3%. Acquisition of an MDR strain was independently associated with admission from a long-term care facility (odds ratio [OR], 9.78; 95% confidence interval [CI], 1.94 to 49.16), previous therapy with fluoroquinolones (OR, 5.52; 95% CI, 1.30 to 23.43) or oxyimino-cephalosporins (OR, 4.72; 95% CI, 1.31 to 16.99), urinary catheterization (OR, 3.89; 95% CI, 1.50 to 10.09), and previous hospitalization (OR, 2.68; 95% CI, 10.4 to 6.89). Patients with MDR P. mirabilis BSIs received inadequate initial antimicrobial therapy (IIAT, i.e., treatment with drugs to which the isolate displayed in vitro resistance) more frequently than those with non-MDR infections; they also had increased mortality and (for survivors) longer post-BSI-onset hospital stays. In multivariate regression analysis, 21-day mortality was associated with septic shock at BSI onset (OR, 12.97; 95% CI, 32.2 to 52.23), P. mirabilis isolates that were MDR (OR, 6.62; 95% CI, 16.4 to 26.68), and IIAT (OR, 9.85; 95% CI, 26.7 to 36.25), the only modifiable risk factor of the 3. These findings can potentially improve clinicians' ability to identify P. mirabilis BSIs likely to be MDR, thereby reducing the risk of IIAT--a major risk factor for mortality in these cases--and facilitating the prompt implementation of appropriate infection control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.